Co-Diagnostics develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Co. may sell diagnostic equipment from other manufacturers as self-contained lab systems. Co. has a portable polymerase chain reaction (PCR) device that is designed to bring PCR to patients in point-of-care and even at-home settings. Co.'s diagnostics systems enable molecular testing for organisms and genetic diseases by automating procedures in both the development and administration of tests. The CODX stock yearly return is shown above.
The yearly return on the CODX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CODX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|